Dlycogen synthase kinase-3 overexpression replicates electroretinogram anomalies of offspring at high genetic risk for schizophrenia and bipolar disorder

Biological Psychiatry

Volumn 76, Issue 2, 2014, Pages 93-100

  Lavoie, Joëlle ^a,b,c   Hébert, Marc ^a,c   Beaulieu, Jean Martin ^a,b  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^b Department of Psychiatry and Neuroscience and Ophthalmology ^*  (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Biomarker; bipolar disorder; electroretinogram; glycogen synthase kinase 3; risk factor; schizophrenia

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 ALPHA; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; BIPOLAR DISORDER; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; ELECTRORETINOGRAM; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CONE; RETINA DISEASE; RETINA ROD; RISK ASSESSMENT; SCHIZOPHRENIA; WESTERN BLOTTING; ANIMAL; ELECTRORETINOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; PHYSIOLOGY; RETINA; RISK FACTOR; TRANSGENIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; ELECTRORETINOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, TRANSGENIC; RETINA; RISK FACTORS; SCHIZOPHRENIA;

EID: 84903190293     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.08.035     Document Type: Article

References (52)

1. M. Hebert, M. Dumont, and P. Lachapelle Electrophysiological evidence suggesting a seasonal modulation of retinal sensitivity in subsyndromal winter depression J Affect Disord 68 2002 191 202
2. M. Hebert, C.W. Beattie, E.M. Tam, L.N. Yatham, and R.W. Lam Electroretinography in patients with winter seasonal affective disorder Psychiatry Res 127 2004 27 34
3. M.P. Lavoie, R.W. Lam, G. Bouchard, A. Sasseville, M.C. Charron, and A.M. Gagne et al. Evidence of a biological effect of light therapy on the retina of patients with seasonal affective disorder Biol Psychiatry 66 2009 253 258
4. R.W. Lam, C.W. Beattie, A. Buchanan, and J.A. Mador Electroretinography in seasonal affective disorder Psychiatry Res 43 1992 55 63
5. Z. Balogh, G. Benedek, and S. Keri Retinal dysfunctions in schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 32 2008 297 300
6. R. Warner, J. Laugharne, M. Peet, L. Brown, and N. Rogers Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: A pilot study Biol Psychiatry 45 1999 1138 1142
7. E.R. Ritvo, D. Creel, G. Realmuto, A.S. Crandall, B.J. Freeman, and J.B. Bateman et al. Electroretinograms in autism: A pilot study of b-wave amplitudes Am J Psychiatry 145 1988 229 232
8. M. Roy, D. Smelson, and A. Roy Longitudinal study of blue cone retinal function in cocaine-withdrawn patients Biol Psychiatry 41 1997 252 253
9. M. Hebert, A.M. Gagne, M.E. Paradis, V. Jomphe, M.A. Roy, and C. Merette et al. Retinal response to light in young nonaffected offspring at high genetic risk of neuropsychiatric brain disorders Biol Psychiatry 67 2010 270 274
10. J.M. Beaulieu A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health J Psychiatry Neurosci 37 2012 7 16
11. R.S. Jope Glycogen synthase kinase-3 in the etiology and treatment of mood disorders Front Mol Neurosci 4 2011 16
12. D.R. Alessi, and P. Cohen Mechanism of activation and function of protein kinase B Curr Opin Genet Dev 8 1998 55 62
13. D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, and B.A. Hemmings Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B Nature 378 1995 785 789
14. O. Kaidanovich-Beilin, and J.R. Woodgett GSK-3: Functional insights from cell biology and animal models Front Mol Neurosci 4 2011 40
15. S. Kapur, and G. Remington Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia Annu Rev Med 52 2001 503 517
16. D. Hoyer, J.P. Hannon, and G.R. Martin Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol Biochem Behav 71 2002 533 554
17. P. Seeman, D. Weinshenker, R. Quirion, L.K. Srivastava, S.K. Bhardwaj, and D.K. Grandy et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis Proc Natl Acad Sci U S A 102 2005 3513 3518
18. S.H. Snyder The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor Am J Psychiatry 133 1976 197 202
19. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc Natl Acad Sci U S A 93 1996 8455 8459
20. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu Rev Pharmacol Toxicol 49 2009 327 347
21. J.M. Beaulieu, S. Marion, R.M. Rodriguiz, I.O. Medvedev, T.D. Sotnikova, and V. Ghisi et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior Cell 132 2008 125 136
22. X. Li, K.M. Rosborough, A.B. Friedman, W. Zhu, and K.A. Roth Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics Int J Neuropsychopharmacol 10 2007 7 19
23. H. Alimohamad, N. Rajakumar, Y.H. Seah, and W. Rushlow Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum Biol Psychiatry 57 2005 533 542
24. K. Nakata, B.K. Lipska, T.M. Hyde, T. Ye, E.N. Newburn, and Y. Morita et al. DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms Proc Natl Acad Sci U S A 106 2009 15873 15878
25. B.K. Lipska, T. Peters, T.M. Hyde, N. Halim, C. Horowitz, and S. Mitkus et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs Hum Mol Genet 15 2006 1245 1258
26. E.S. Emamian, D. Hall, M.J. Birnbaum, M. Karayiorgou, and J.A. Gogos Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia Nat Genet 36 2004 131 137
27. H.Y. Tan, A.G. Chen, Q. Chen, L.B. Browne, B. Verchinski, and B. Kolachana et al. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications Mol Psychiatry 17 2012 1007 1016
28. H.Y. Tan, K.K. Nicodemus, Q. Chen, Z. Li, J.K. Brooke, and R. Honea et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans J Clin Invest 118 2008 2200 2208
29. J.M. Beaulieu, X. Zhang, R.M. Rodriguiz, T.D. Sotnikova, M.J. Cools, and W.C. Wetsel et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency Proc Natl Acad Sci U S A 105 2008 1333 1338
30. X. Zhang, R.R. Gainetdinov, J.M. Beaulieu, T.D. Sotnikova, L.H. Burch, and R.B. Williams et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression Neuron 45 2005 11 16
31. A.J. Law, Y. Wang, Y. Sei, P. O'Donnell, P. Piantadosi, and F. Papaleo et al. Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy Proc Natl Acad Sci U S A 109 2012 12165 12170
32. K.K. Nicodemus, A.J. Law, E. Radulescu, A. Luna, B. Kolachana, and R. Vakkalanka et al. Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls Arch Gen Psychiatry 67 2010 991 1001
33. K.K. Nicodemus, A.J. Law, A. Luna, R. Vakkalanka, R.E. Straub, and J.E. Kleinman et al. A 5' promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression Mol Psychiatry 14 2009 741 743
34. Y. Sei, R. Ren-Patterson, Z. Li, E.M. Tunbridge, M.F. Egan, and B.S. Kolachana et al. Neuregulin1-induced cell migration is impaired in schizophrenia: Association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms Mol Psychiatry 12 2007 946 957
35. S. Amar, G. Shaltiel, L. Mann, A. Shamir, B. Dean, and E. Scarr et al. Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia Int J Neuropsychopharmacol 11 2008 197 205
36. M. Li, Y. Mo, X.J. Luo, X. Xiao, L. Shi, and Y.M. Peng et al. Genetic association and identification of a functional SNP at GSK3beta for schizophrenia susceptibility Schizophr Res 133 2011 165 171
37. G. Blasi, F. Napolitano, G. Ursini, A. Di Giorgio, G. Caforio, and P. Taurisano et al. Association of GSK-3beta genetic variation with GSK-3beta expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia Am J Psychiatry 170 2013 868 876
38. Y.J. Lee, and Y.K. Kim The impact of glycogen synthase kinase 3beta gene on psychotic mania in bipolar disorder patients Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1303 1308
39. E. Saus, V. Soria, G. Escaramis, J.M. Crespo, J. Valero, and A. Gutierrez-Zotes et al. A haplotype of glycogen synthase kinase 3beta is associated with early onset of unipolar major depression Genes Brain Behav 9 2010 799 807
40. F. Benedetti, S. Poletti, D. Radaelli, A. Bernasconi, R. Cavallaro, and A. Falini et al. Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity Genes Brain Behav 9 2010 365 371
41. B. Inkster, T.E. Nichols, P.G. Saemann, D.P. Auer, F. Holsboer, and P. Muglia et al. Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder Arch Gen Psychiatry 66 2009 721 728
42. W.T. O'Brien, J. Huang, R. Buccafusca, J. Garskof, A.J. Valvezan, and G.T. Berry et al. Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice J Clin Invest 121 2011 3756 3762
43. K.P. Hoeflich, J. Luo, E.A. Rubie, M.S. Tsao, O. Jin, and J.R. Woodgett Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation Nature 406 2000 86 90
44. K. MacAulay, B.W. Doble, S. Patel, T. Hansotia, E.M. Sinclair, and D.J. Drucker et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism Cell Metab 6 2007 329 337
45. J.M. Beaulieu, T.D. Sotnikova, W.D. Yao, L. Kockeritz, J.R. Woodgett, and R.R. Gainetdinov et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade Proc Natl Acad Sci U S A 101 2004 5099 5104
46. J. Lavoie, P. Illiano, T.D. Sotnikova, R.R. Gainetdinov, J.M. Beaulieu, and M. Hebert The electroretinogram as a biomarker of central dopamine and serotonin: Potential relevance to psychiatric disorders [published online ahead or print January 7] Biol Psychiatry 2013
47. M. Hebert, P. Lachapelle, and M. Dumont Reproducibility of electroretinograms recorded with DTL electrodes Doc Ophthalmol 91 1995 333 342
48. K.I. Naka, and W.A. Rushton S-potentials from colour units in the retina of fish (Cyprinidae) J Physiol 185 1966 536 555
49. S.J. Glatt, I.P. Everall, W.S. Kremen, J. Corbeil, R. Sasik, and N. Khanlou et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia Proc Natl Acad Sci U S A 102 2005 15533 15538
50. R.W. Lam, S. Allain, K. Sullivan, C.W. Beattie, R.A. Remick, and A.P. Zis Effects of chronic lithium treatment on retinal electrophysiologic function Biol Psychiatry 41 1997 737 742
51. R. Kuepper, M. Skinbjerg, and A. Abi-Dargham The dopamine dysfunction in schizophrenia revisited: New insights into topography and course Handb Exp Pharmacol 212 2012 1 26
52. P. Witkovsky Dopamine and retinal function Doc Ophthalmol 108 2004 17 40